AACR 2022

View All

AACR 2022: Novartis shifting focus towards directly targeting KRASG12c after disappointment from SHP2 inhibitor, TNO155.

Post Lumakras ‘approval,  Adagrasib’s PDUFA date, Novartis now ready to enter the KRASG12C space Novartis is now heading towards its unique KRASG12C inhibitor in patients with advanced non-small cell lung cancer (NSCLC). The company presented the promising preliminary data (Phase Ib) from the KontRASt-01 study e...

Find More

tigit immunotherapy
AACR 2022 updates, recent disappointment, deals and collaboration of TIGIT immunotherapies

TIGIT (T cell immunoreceptor with Ig and ITIM domains) - The red hot corner of immune-oncology market drawing huge Interest Interest in TIGIT has increased since last 2-3 years and several key players are now active in this field including BeiGene’s Ociperlimab, which is in Phase III stage of development fo...

Find More

AACR 2022 - LAG 3 Immunotherapy
AACR 2022: LAG-3, one of the most trending Next-generation Immunotherapy

Updates on F-star Therapeutics’ and Akeso’s Bi-specific Antibody targeting LAG-3 and PD-L1 F-star Therapeutics presented the preclinical mechanistic data on the Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022. The data demonstrated that the tetravalent and unique structure of FS118 played a ...

Find More